Skip to content

Trial Summary

The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously.



ACTRN/NCT /ethics:


Scientific title:

A Randomized Phase-III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Sponsor / Cooperative group:

Canadian Cancer Trials Groups

Trial & Patient Characteristics

Cancer TypeMelanoma & other skin
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
Tumour Stream Melanoma
Cancer StageMetastatic or Widespread
Anticipated Start Date2016-07-04
Anticipated End Date2029-12-31

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Phone08 8222 6140
Principal InvestigatorDr Rachel Roberts-Thomson
Recruitment StatusRecruiting